Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis by Ciccia, F. et al.
Original article
Potential involvement of IL-9 and Th9 cells in the
pathogenesis of rheumatoid arthritis
Francesco Ciccia1,*, Giuliana Guggino1,2,*, Aroldo Rizzo3, Antonio Manzo4,
Barbara Vitolo4, Marco Pio La Manna2, Giuseppina Giardina2, Guido Sireci2,
Francesco Dieli2, Carlo Maurizio Montecucco4, Riccardo Alessandro2 and
Giovanni Triolo1
Abstract
Objective. IL-9 has been shown to be upregulated before the clinical onset of articular disease in RA. The
exact role of IL-9 and Th9 cells in RA, however, has not yet been adequately studied. The aim of this
study was to evaluate the expression of IL-9 and IL-9-expressing cells in RA patients.
Methods. IL-9, IL-9R, PU.1, IL-9, thymic stromal lymphopoietin (TSLP), IL-4 and TGF-b expression was
assessed by real-time-PCR in the synovial tissues of RA and OA patients. IL-9, IL-9R, IL-4, TSLP and
TGF-b were also investigated by immunohistochemistry. Peripheral CD4+ T cell subsets were studied by
flow cytometry analysis before and after incubation with citrullinated peptides.
Results. IL-9 was overexpressed in RA synovial tissues and correlated with the degree of histological
organization of B and T cells in ectopic lymphoid structures. The majority of IL-9-producing cells
were identified as CD3+ cells. Increased mRNA and protein expression of IL-9R, IL-4, TSLP and TGF-b
was also observed in RA synovial tissue. Blood peripheral Th9 cells were expanded by citrullinated
peptides.
Conclusion. These results indicate that Th9 cells and IL-9 were frequently detected in peripheral
blood mononuclear cells and synovia of RA patients. A possible pathogenic role for Th9 in RA is
discussed.
Key words: IL-9, Th9 cells, rheumatoid arthritis, citrullinated peptide.
Rheumatology key messages
. IL-9 and Th9 cells are present in RA patients.
. IL-9 expression in RA patients is correlated with the degree of synovial inflammatory infiltrate and ectopic lymph-
oid follicle organization.
. Stimulation with citrullinated peptides results in the expansion of Th9 cells in RA patients.
Introduction
RA is a chronic autoimmune disease characterized by
joint erosion and damage. Altered expression of several
cytokines and recruitment of auto-reactive lymphocytes to
inflamed tissue is a defined feature of the disease [1].
Auto-reactive T cells in RA seem to be characterized by
a marked shift towards the Th1 and Th17 phenotype, with
overproduction of IFN-g and IL-17, altered Treg function
and inadequate production of Th2 cytokines [1]. In add-
ition to Th1, Th17 and Th2 cells, another subset of effector
T cells, identified by the production of IL-9 and named Th9
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cells, with a potential role in T-cell-dependent B-cell dif-
ferentiation, expansion and antibody production, has also
been described [2, 3]. The development of Th9 cells
requires a balance of signals from cytokines such as
IL-4 and TGF-b [2], and from epithelial cytokines such
as thymic stromal lymphopoietin (TSLP) [4].
All these cytokines have been demonstrated to be
increased in RA [57] and to induce the transcription
factor PU.1 that acts in recruiting chromatin-modifying
enzymes and activating gene expression [8]. A role for
IL-9 in RA is also suggested by the demonstration of its
increased levels before the clinical onset of articular dis-
ease [9]. Although these observations overall suggest a
potential role for IL-9 in RA, the exact role of Th9/IL-9
has not yet been adequately studied.
The aim of the present study was to assess whether
the Th9 subset occurs in the synovial tissue of patients
with RA and correlates with the degree of histological
organization and to analyse the frequency of Th9 cells in
the peripheral blood of RA patients. The role of a
citrullinated peptide in in vitro Th9 activation was also
evaluated.
Here we show for the first time that IL-9 and Th9 cells
are overexpressed in RA synovial tissue and correlate with
the degree of histological organization of B and T cells in
ectopic lymphoid structures. We also show that peripheral
Th9 cells are increased in RA and specifically activated by
citrullinated peptides. Altogether, these results suggest
that Th9 cells and IL-9 may play an important role in the
pathogenesis of RA.
FIG. 1 IL-9 in RA synovial tissues
(AC) Relative m-RNA quantification of IL-9 (A), IL-9R (B) and PU.1 (C) was assessed by quantitative RT-PCR in synovial
samples obtained from 18 RA and 15 OA patients. Experiments were performed in triplicate and data were calculated as
means of experimental triplicates. (D) IL-9m-RNA expression was correlated with the degree of inflammatory infiltrate
and lymphoid organization. (EH) Representative microphotographs showing IL-9 immunostaining of RA (n=36) (EG),
and OA (n=15) patients (H); experiments were performed in triplicate. (IN) Sequential sections of RA synovial tissues
with diffuse infiltrate (IK) and aggregate (L and M) stained for CD3, CD20 and IL-9. IL-9 was expressed particularly in
synovial tissues of RA patients showing a high degree of inflammatory infiltrate (F and K) or lymphoid follicle (G and N).
(EN) Original magnification 250. (O) Quantification of IL-9+ cells in RA synovial tissues displaying germinal centres,
aggregates of inflammatory cells without germinal centres and diffuse infiltration of inflammatory cells.
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Materials and methods
Immunohistochemistry in synovial tissues
Immunohistochemical analysis for CD3, CD19, CD21, IL-9,
IL-9R, IL-17, PU.1 and TSLP was performed on 5-mm-thick
paraffin-embedded sections from synovial biopsies and
from tonsils (used as positive controls), as previously
described [10]. Each sample was obtained by arthroscopy
or arthroplasty from 36 RA biologic-naive patients [28
female, mean duration of disease 51 (S.D. 12) months,
DAS28 6.6 (S.D. 2.8)] who fulfilled the 2010 ACR/EULAR
classification criteria [11]. At the time of synovial biopsy,
all patients were receiving a low dose of steroids
(<7.5mg daily prednisone), 7 were not receiving any
DMARDs, 21 were receiving MTX (>10mg weekly) and 8
were receiving LEF therapy. OA synovial biopsies were
FIG. 2 Th9 in RA synovial tissues
The IL-9 source in RA and OA synovial tissue was assessed by confocal microscopy analysis in 10 RA patients and 10 OA
patients. Experiments were performed in triplicate. (AC) CD3+ cells were the major source of IL-9; (A and B) single
staining for CD3 (A) and IL-9 (B), respectively. (C) Merged double staining for CD3 (green) and IL-9 (red). (DF) Th17 in RA
synovial tissues. (D and E) Single staining for IL-17 and IL-9, respectively. (F) Merged double staining for IL-17 (green) and
IL-9 (red). (GI) Th9 in RA synovial tissues. (G and H) Single staining for PU.1 and IL-9, respectively. (I) Merged double
staining for PU.1 (green) and IL-9 (red). (JL) Th9 cells in OA synovial tissue. (JK) Single staining for PU.1 and IL-9,
respectively. (L) Merged double staining for PU.1 (green) and IL-9 (red).
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obtained from 15 patients with end-stage disease undergo-
ing knee joint replacement surgery and were included as
controls. All participants gave their informed consent, and
the study was approved by the university hospital ethics
committee (Azienda Ospedaliera Universitaria Paolo
Giaccone, University of Palermo, Palermo, Italy). Synovial
biopsy samples were fixed in formalin, and haematoxylin
and eosinstained sections were studied by the same path-
ologist (A.R.) using a microscope equipped with an ocular
micrometer. Evaluation of the presence of lymphocytic in-
filtrates and/or synovial hyperplasia was performed by two
investigators independently (F.C. and A.R.). Biopsies were
grouped according to the following criteria: TB cell aggre-
gates with germinal centres (GCs), TB cell aggregates
without GCs or diffuse infiltration of T and B cells without
lymphoid organization. The presence of GCs within lymph-
oid aggregates was determined according to standard
histological criteria [12].
Sections were incubated with unlabelled rabbit-
anti-human-IL-9 (Novus Biologicals, Littleton, CO, USA),
mouse-anti-human-PU.1 (Novus Biologicals, Littleton, CO,
USA), rabbit-anti-human-IL-17 (Santa Cruz, CA, USA) and
rabbit anti-human TSLP (Novus Biologicals, Littleton, CO,
USA). To characterize Th9 cells, double staining was per-
formed on paraffin-embedded sections of human synovial
tissues. Sections were incubated with unlabelled anti-
human IL-9 and PU.1 antibodies (Th9 cells), and IL-9 and
IL-17 (Th17 cells), then treated with FITC- or rhodamine
redconjugated anti-mouse or anti-rabbit antibodies plus
RNasi (200ng/ml) and counterstained using Toto-3 iodide
(642/660; Invitrogen). Confocal analysis was used to ac-
quire fluorescence staining.
RNA isolation and quantitative real-time PCR
Synovial biopsies obtained from 18 of the 36 patients with
RA and from all OA patients, soon after removal, were
stored in RNAlater solution (Applied Biosystems, Foster
City, CA, USA). Real-time PCR was performed as previ-
ously described [13]. Master mix and Taqman gene
expression assays for GAPDH control and target genes
IL-9 (Hs00914237_m1), IL-9R (Hs01108522_m1), IL-4
(Hs00174122-m1), TGF-b (Hs00998133_m1), TSLP
FIG. 3 IL-9R expression in RA synovial tissues
IL-9R expression in RA synovial tissue was assessed by immunohistochemistry in 36 RA patients and 15 OA patients.
Experiments were performed in triplicate. Representative microphotographs showing CD3 (A, D and G), CD20 (B, E and
H) and IL-9R+ cells (C, F and I) in paraffin-embedded synovial samples obtained from RA patients without (AC) and with
(DF and GI) TB cell aggregates. Diffuse positive cells were detected outside TB cell aggregates (C, F and I), with few
cells detectable at the outside border of lymphoid aggregates (F and I). (AI) original magnification 250.
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(Hs00263639_m1), PU.1 (Hs00162150_m1), IFN-g
(Hs00989291_m1), IL-21 (Hs00222327_m1) and IL-27
(Hs00377366_m1) were obtained from Applied
Biosystems (Foster City, CA, USA). Final values were ex-
pressed as fold induction.
Patients and culture conditions
Peripheral blood samples were obtained from 15 of the
above-described RA patients with established disease
[12 female, mean age 48 (S.D. 6)], from 20 new patients
with early untreated RA [14 female; mean age 32 (S.D. 14),
mean disease duration 11 (S.D. 4) months] who fulfilled the
2010 ACR/EULAR classification criteria [14] and from 16
sex- and age-matched healthy controls. These patients
had active disease as defined by the presence of six or
more swollen joints and six or more tender joints at base-
line, and either a CRP level of52mg/dl and/or an ESR of
530mm/h (DAS >5.1) at screening. All participants gave
their informed consent, and the study was approved by
the university hospital ethics committee. Peripheral blood
mononuclear cells (PBMCs) were isolated from hepari-
nized blood samples by Ficoll-Hypaque (Sigma) density-
gradient centrifugation. RPMI 1640 medium supple-
mented with 2 nM L-glutamine, 5mM HEPES, 100 U/ml
penicillin or 10 mg/ml streptomycin, 0.5mM sodium pyru-
vate, 0.05mM of non-essential amino acids (both ob-
tained from Life Technologies) and 10% fetal calf serum
(obtained from BioWhittaker) were used to assess all ex-
periments. Cell viability (trypan blue dye exclusion) was
always >95%. PBMCs were cultured with phorbol myris-
tate acetate (50 ng/ml; Sigma, St Louis, MO, USA) and
ionomycin (1 mg/ml; Sigma, St Louis, MO, USA) and incu-
bated at 37C in 5% CO2. After 2 h of incubation, Brefeldin
A (10mg/ml; Sigma, St Louis, MO, USA) was added, and
FIG. 4 IL-4, TGF-b and TSLP expression in RA synovial tissues
IL-4, TGF-b and TSLP expression in RA synovial tissue was assessed by real-time PCR and immunohistochemistry in 36
RA patients and 15 OA patients. (A, E and I) real-time PCR expression of IL-4 (A), TGF-b (E) and TSLP (I) in RA patients
and controls. Strong IL-4 immunoreactivity was observed in the infiltrating mononuclear cells of RA synovial tissue (B),
but not in OA synovial tissues (C). Strong TGF-b expression was found in both the infiltrating mononuclear cells and the
synovial layer of RA synovial samples (F), but not in OA synovial tissues (G). TSLP expression was observed mainly in RA
synovia in the context of the synovial layer (J) and in endothelial cells of neovessels (J insert); some infiltrating inflam-
matory mononuclear cells were also TSLP positive. In control synovial samples, TSLP expression was observed only in
the context of endothelial cells (K). Isotype control staining for IL-4 (D), TGF-b (H) and TSLP (L). (BD, FH, JL) original
magnification 250. TSLP: thymic stromal lymphopoietin.
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after 16 h of incubation, cells were collected and stained
with the following mAbs: anti-human-CD4-PerCP (BD
Biosciences, San Jose, CA, USA), anti-human-
PU.1-FITC (R&D Systems, La Jolla, CA, USA), anti-
human IL-9-PE (BD Biosciences, San Jose, CA, USA),
anti-human-IL-17-APC, anti-human IFN-g- FITC (BD
Biosciences, San Jose`, CA, USA) and anti-human
FoxP3-FITC (R&D Systems, La Jolla, CA, USA). Isotype-
matched irrelevant antibodies were used as negative con-
trol. The cells were incubated with mAbs for 30min on ice
and washed twice in PBS containing 0.1% (w/v) NaN3
(Sigma Aldrich). After surface staining, the cells were
fixed with 2% (w/v) paraformaldehyde (Sigma, St Louis,
MO, USA) for 30min at 4C and then treated with a per-
meabilization solution (BD Biosciences, San Jose, CA,
USA) for 10 min at room temperature and stained with
antibodies for intracellular antigens for 30min at 4C.
PBMCs (106/ml) were stimulated with aggrecan peptide
and with citrullinated arthritogenic aggrecan peptide at a
final concentration of 25 mg/ml for 16 h at 37C in 5% CO2.
Citrullinated and non-citrullinated aggrecan peptide were
synthesized using a commercially available synthesis
service (Chem Progress, San Vittore Olona, Milan, Italy)
with the arginine/citrulline substitution underlined in the
following sequence VVLLVATEGR/CitVRVNSAYQDK;
the citrullination was verified by mass spectrometry
(Chem Progress, San Vittore Olona, Milan, Italy). Flow
cytometry analysis was performed using a FACSCalibur
(BD Biosciences, San Jose`, CA, USA). At least 50 000
events, gated on the lymphocyte region, were acquired
for each sample.
Statistical analysis
Analyses were performed using GraphPad Prism software
(version 5.0; GraphPad Software). Multiple groups were
analysed using one-way analysis of variance and pairwise
comparisons using the MannWhitney U test, with
Bonferroni’s correction to adjust significance levels for
multiple comparisons where appropriate. Correlation
analyses were performed by using the Spearman’s rank
correlation coefficient. P< 0.05 was considered
significant.
Results
IL-9, IL-4, TGF-b, TSLP and Th9 expression in RA
synovial samples
Synovial tissues from RA patients were first analysed for
the topographical organization of the inflammatory
infiltrates. Fifteen RA patients (41.6%) displayed diffuse
infiltrates of inflammatory cells without aggregates of spe-
cific microstructures. TB cell aggregates without GC
organization were observed in 10 patients (27.7%),
whereas aggregation of inflammatory cells in secondary
follicles with GC formation was observed in 11 patients
(30.5%). We next evaluated the synovial expression of IL-
9, IL-9R, PU.1, IFNg, IL-21 and IL-27 in patients with RA
and OA. A significant upregulation of IL-9, IL-9R and
FIG. 5 Correlation between IL-9-expressing cells and IL-4-, TGF-b- and TSLP-expressing cells
(A) The number of IL-4-expressing cells was correlated with the number of IL-9-expressing cells (r2 0.6705, P< 0.0001);
(B) the number of TGF-b-expressing cells was correlated with the number of IL-9-expressing cells (r2 0.4138, P< 0.0001);
(C) the number of TSLP-expressing cells was correlated with the number of IL-9-expressing cells (r2 0.6325, P< 0.0001).
The r2 and P-values were determined using Spearman’s correlation coefficient.
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PU.1m-RNA was observed in the synovium of RA patients
compared with OA patients (Fig. 1AC), IL-9 expression
being correlated with the level of inflammatory infiltrate
organization (Fig. 1D). IFN-g and IL-27, but not
IL-21, were also significantly upregulated in RA synovia
(4- and 6-fold increase, respectively), but their levels
were not correlated with IL-9 (data not shown). IL-9 was
detected by immunohistochemistry in all the RA biopsies,
mainly among synovial fibroblasts and infiltrating mono-
nuclear cells (Fig. 1EG). Conversely, weak IL-9 expres-
sion was observed in OA patients (Fig. 1H). In RA, IL-9
expression was directly correlated with the degree of in-
flammatory infiltrate and lymphoid organization (Fig. 1IO).
IL-9-expressing cells were confirmed to be mainly Th9
FIG. 6 Characterization of IL-9-producing cells and activation of CD4+ T cells after in vitro stimulation with aggrecan
citrullinated peptide
(A and B) Representative dot plot showing IL-9+IL-17+ cells (Th17 cells) among peripheral blood mononuclear cells
(PBMCs) of RA patients (A) and controls (B). (C and D) Representative dot plot showing IL-9+PU.1+ cells (Th9 cells)
among PBMCs of RA patients (C) and controls (D). (E and F) Representative dot plot showing IL-9+FOXP3+ cells (Treg
cells) among PBMCs of RA patients (E) and controls (F). (G) Percentages of Th9 cells in RA patients and controls.
*P< 0.05 vs controls. (H) Percentages of IL-9+ cells among Th9, Th17 and Treg cells in RA patients and controls. (I and J)
Percentages of CD4+IL-9+PU.1+ cells among PBMCs of patients (I) and controls (J) stimulated with aggregan and cit-
aggrecan peptides.**P< 0.05 vs all other groups. Experiments were performed in triplicate.
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cells by confocal microscopy analysis, which demon-
strates the predominant CD3 (Fig. 2AC), but not CD19/
CD68 (data not shown), expression of IL-9+ cells and the
predominant co-expression of IL-9 with PU.1 (Fig. 2GI).
A weak degree of co-localization was, however, observed
between IL-9 and IL-17 (Fig. 2DF), suggesting that Th17
cells produce IL-9 in RA. No Th9 cells were detected in OA
synovial samples (Fig. 2JL). IL-9R protein expression
was confirmed in all RA synovial tissues (Fig. 3). Positive
cells showed a diffuse distribution in the sublining, with
few positive cells detectable in the proximity of lymphoid
aggregates (Fig. 3DI). Since Th9 polarization has been
demonstrated to be dependent on IL-4, TGF-b and
TSLP [2, 4], we next evaluated their expression in synovial
tissues from patients and controls. A significant upregula-
tion of IL-4 (Fig. 4AD), TGF-b (Fig. 4EH) and TSLP
(Fig. 4IL) was demonstrated in RA synovial tissues com-
pared with OA synovial tissues, at both m-RNA and pro-
tein level, and the number of IL-4/TGF-b/TSLP-positive
cells was directly correlated with the number of
IL-9-positive cells (Fig. 5). Strong IL-4 staining was
observed in the infiltrating mononuclear cells of RA
patients (Fig. 4B), but not in OA synovial tissues (Fig.
4C). Strong TGF-b expression was found in both the infil-
trating mononuclear cells and the synovial layer of RA
patients (Fig. 4F) but not in OA synovial tissues (Fig. 4G).
TSLP expression was observed mainly in RA in the con-
text of the synovial layer (Fig. 4J) and endothelial cells (Fig.
4J insert); some infiltrating inflammatory mononuclear
cells were also TSLP positive. In control synovial samples,
TSLP expression was observed only among endothelial
cells (Fig. 4K).
Peripheral blood Th9 detection and in vitro expansion
with aggrecan citrullinated peptide
We next evaluated the frequency of IL-9-producing cells
in RA patients and controls. In order to characterize the
phenotype of circulating IL-9-positive cells, the
co-expression of IL-9/IL-17 (Fig. 6A and B), IL-9/PU-1
(Fig. 6C and D) and IL-9/FoxP3 (Fig. 6E and F) was first
evaluated. In RA, the majority of IL-9-producing cells did
not co-express IL-17 or FoxP3 (Fig. 6A, B, E, F and H); a
high percentage of these cells PU.1 positive (Fig. 6C, D
and H). Th9 cells were significantly increased among
PBMCs isolated from established RA [0.5 (S.D. 0.08)] and
early RA [0.3 (S.D. 0.05)] patients compared with controls
[0.017 (S.D. 0.006)] (Fig. 6G). PBMCs from RA patients and
controls were also stimulated with the citrullinated aggre-
can peptide, with the non-citrullinated aggrecan peptide
as control. In RA patients (Fig. 6I and J), but not in controls
(data not shown), after stimulation with the citrullinated
aggrecan peptide we observed a strong and significant
expansion of Th9 and Th17 cells. The response to citrulli-
nated aggrecan (cit-aggrecan) was significantly correlated
with the presence and titre of ACPA (r2= 0.45, P< 0.05)
and was more intense in patients displaying synovial GCs
(data not shown).
Discussion
In the present study we demonstrated, for the first time,
that IL-9 and Th9 cells are overexpressed in RA synovial
tissue and correlate with the degree of histological organ-
ization of B and T cells in ectopic lymphoid structures.
Peripheral blood Th9 cells were found to be increased in
RA, and expanded after in vitro exposure to a citrullinated
peptide.
Although initially characterized as Th2 cell derived, a
new IL-9-producing Th cell subset, namely Th9 cells,
has been demonstrated [2]. Th9 effector cells are distinct
from Th2 cells and can be differentiated in vitro via TCR
stimulation in the presence of TGF-b and IL-4, or directly
in the presence of TSLP [2, 4]. Given the pleiotropic func-
tions of IL-9, Th9 cells might be involved in several types
of inflammatory disease. IL-9 has recently been found to
be increased before the clinical onset of articular disease,
and is associated with the presence of RA-related auto-
antibodies and circulating biomarkers of inflammation [9].
These results and our findings suggest that IL-9 and Th9
cells may make an important contribution to adaptive
immune responses occurring in the inflamed joints of RA
patients.
In our study, a significant expansion of Th9 cells was
observed in the circulation of patients with established
and early RA, independently of disease duration and treat-
ment. IL-9 overexpression was also demonstrated in the
synovial samples of patients with established RA, mainly
expressed by cells of the synovial lining layer and by infil-
trating CD4+ T cells expressing the Th9-specific factor
PU.1 (identified as Th9 cells). The development of Th9
cells requires a balance of signals from cytokines that
would otherwise generate distinct Th subsets, such as
IL-4 and TGF-b [2], and epithelial cytokines such as
TSLP [4], which results in the induction of PU.1. IL-9
overexpression in RA was accompanied by a significant
increased expression of IL-4, mainly among infiltrating
mononuclear cells—indicating an involvement of adaptive
immunity in regulating Th9 development, and highlighting
the complexity of immune system dysregulation in RA. In
this study, we also showed that TSLP is strongly upregu-
lated in the synovial layer of RA tissues and is directly
correlated with the IL-9 expression. TSLP has been
demonstrated to belong to the innate branch of immunity
and to drive, also independently of canonical cytokines,
the development of Th9 cells. In relation to this, TSLP
levels have been found to be significantly increased in
SF of RA patients and capable of stimulating TSLP recep-
tor-expressing CD11c+ myeloid dendritic cells to secrete
chemokines, causing influx and subsequent activation of
CD4+ T cells [7].
The strong connection between IL-9 and autoimmunity
has also recently been highlighted by the demonstration
of its potential role in T-cell-dependent B-cell differenti-
ation, expansion and antibody production [3]. The
correlation between IL-9 and lymphoid organization
that we observed in the present study further confirms,
in our opinion, the importance of IL-9 and IL-9-producing
cells in the induction of autoimmunity in RA. In this
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regard, our demonstration of a strong expression of IL-9R
(m-RNA and protein) in the synovium of RA patients,
especially in those synovial samples displaying the
presence of GCs, seems to be relevant. IL-9R has
been demonstrated by Fawaz et al. [3] to be expressed
in GC B cells, and its expression seems to be func-
tional, because stimulation with IL-9 results in upregula-
tion of phosphorylation of the transcription factors
signal transducer and activator of transcription (STAT)3
and STAT5 and the ability of IL-9 to potentiate IgE
production.
As for other human autoimmune diseases, RA suscepti-
bility and severity are linked to multiple genes [15], but the
strongest genetic association exists with the HLA-DRB1
genes, and in particular the HLA-DR4 alleles. There is a
clear association between these alleles and peptide citrul-
lination, as recently demonstrated by Scally et al. [16].
Citrullinated arthritogenic aggrecan peptide has been con-
sidered to be a biomarker of RA, having been identified in
the peripheral blood of RA patients and shown to stimulate
a specific CD4 response. It is considered a candidate auto-
antigen for RA, being one of the principle proteoglycans for
cartilage extracellular matrix functioning in cushioning syn-
ovial joints, self-antigens that share a common sequence at
position 7074 of the HLA-DR bchain in 90% of RA
patients. Our demonstration that stimulation with the arthri-
togenic aggrecan peptide results, in RA patients, in a
strong and significant expansion of Th9 cells might suggest
the existence of an association between citrullination
and autoreactive Th9 cells. In conclusion, in this study we
provide data on a potential role for IL-9 and IL-9-producing
cells in the pathogenesis of RA. More studies are, however,
required to better elucidate the functional and pathogenic
role of IL-9 and Th9 cells in RA.
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